Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Amgen’s latest 10-K can feel like navigating a clinical-trial protocol—hundreds of pages on biologics manufacturing, FDA milestones and patent cliffs. If you’ve ever searched for “Amgen insider trading Form 4 transactions” or tried to pinpoint R&D spend buried deep in a footnote, you know the challenge. Biotech disclosures are dense because every molecule, royalty agreement and safety signal can move AMGN’s valuation.
Stock Titan turns those complexities into clarity. Our AI-powered summaries spotlight what matters in each Amgen SEC filing—whether it’s a “quarterly earnings report 10-Q filing” that explains Prolia sales trends or an “8-K material events explained” alert when a Phase 3 study stops early. Real-time feeds surface “Amgen Form 4 insider transactions real-time” so you can monitor executive stock transactions before the market reacts. Need the big picture? The “annual report 10-K simplified” section distills pipeline probabilities, biosimilar headwinds and manufacturing capacity in plain English.
Use the platform to:
- Scan “Amgen proxy statement executive compensation” details to see how scientists are incentivized.
- Compare segment margins across quarters with our “Amgen earnings report filing analysis”.
- Dive into “Amgen SEC filings explained simply” for each form type—from S-8 share plans to 10b5-1 trading plans.
No more rummaging through PDFs. With real-time updates from EDGAR and AI that translates biotech jargon, understanding Amgen SEC documents with AI becomes straightforward—helping investors, analysts and healthcare professionals make informed decisions faster.
Amgen Inc. (AMGN) senior vice president and chief compliance officer Nancy A. Grygiel reported option exercises and related stock sales. On 11/20/2025, she exercised options to buy 1,500 shares of common stock at $177.46 per share and 1,639 shares at $162.60 per share, then sold 1,500 shares and 1,639 shares of common stock at an average price of $337.2625 per share.
After these transactions, she directly beneficially owned 7,225 shares of Amgen common stock, which include 96 dividend equivalent units tied to unvested RSUs, and also held 104.6847 shares through the company 401(k) plan’s stock fund. She continued to hold 1,970 nonqualified stock options from the 04/27/2020 grant, while the 05/01/2019 option grant was fully exercised.
Amgen (AMGN) insider transaction: The company’s SVP of Business Development reported a sale of 890 shares of Amgen common stock on 11/12/2025 (Transaction Code S) at an average price of $336.2422. The filing notes trade prices ranged from $336.2219 to $336.30 per share. Following the transaction, the reporting person beneficially owns 7,082 shares, held directly. This balance includes 93 Dividend Equivalents credited to unvested RSUs under Amgen’s equity plan.
Amgen (AMGN) insider transaction: EVP, Global Commercial Ops Murdo Gordon filed a Form 4 reporting an open‑market sale of 6,879 shares of common stock on 11/12/2025 at an average price of $336.8326.
After the trade, Gordon beneficially owns 41,923 shares. This figure includes 647 dividend equivalents (DEs) credited to unvested RSUs under Amgen’s equity plan, which pay out in shares on a one‑to‑one basis according to the vesting schedule.
Amgen (AMGN) reported insider activity by its EVP & Chief Technology Officer. On 11/11/2025, the officer made a gift of 6,490 shares of common stock, followed by a gift of 309 shares on 11/12/2025, both at $0 per share (Form 4 code G). After these transactions, the officer beneficially owned 35,503 shares.
The filing notes the first gift went to a charitable donor‑advised fund and the second to a non‑profit organization. The reported holdings include 583 dividend equivalents credited to unvested RSUs, payable in shares pursuant to the vesting schedule.
Amgen Inc. (AMGN) reported an insider transaction. Director S. Omar Ishrak acquired 218.6134 shares of Common Stock on 11/07/2025 at $0, increasing his beneficial ownership to 6,507.5436 shares, held directly.
The filing notes these holdings include 338 Dividend Equivalents credited under the Director Program, which are paid in Amgen Common Stock on a one-to-one basis, with cash for any remaining fractional share amount.
Amgen (AMGN) director Charles M. Holley reported acquiring 265.4591 shares of common stock on 11/07/2025 at a stated price of $0. Following the transaction, he beneficially owns 11,834.085 shares directly and 1,260 shares indirectly through the Holley Family Trust. The holdings include 1,393 Dividend Equivalents credited on vested but deferred RSUs, which are paid out in shares on a one-to-one basis.
Amgen (AMGN) reported a director transaction. On 11/07/2025, the reporting person acquired 218.6134 shares of common stock at $0, reflecting equity credited under the company’s director program.
Following this activity, the director beneficially owned 4,958.6425 shares, held directly. The filing notes these shares include 268 Dividend Equivalents credited on vested but deferred RSUs, which are paid out in shares on a one-to-one basis with cash for any remaining fractional amount.
Amgen Inc. insider filing shows that SVP, Business Development Rachna Khosla reported a transaction dated 11/05/2025. The filing lists a Code F disposition of 226 shares of common stock at $296.7 per share, resulting in 7,972 shares beneficially owned directly. The reported share balance includes 93 Dividend Equivalents tied to unvested RSUs under Amgen’s 2009 Equity Incentive Plan, which are credited and paid in shares on a one-to-one basis according to the vesting schedule.
Amgen (AMGN) officer Matthew C. Busch, VP, Finance & CAO, reported a Form 4 transaction dated 11/05/2025.
He disposed of 202 shares of common stock at $296.70 per share (Transaction Code F). Following the transaction, he beneficially owns 4,414 shares, held directly.
Footnote: the reported holdings include 51 Dividend Equivalents credited on unvested RSUs, which are paid in shares pursuant to plan terms.
Amgen Inc. reported stronger Q3 2025 results. Total revenues rose to $9,557 million from $8,503 million a year ago, driven by product sales of $9,137 million. Net income increased to $3,216 million and diluted EPS was $5.93 versus $5.22 last year, as operating income improved to $2,526 million.
Performance was supported by key brands including Prolia, TEPEZZA, EVENITY, Repatha, and Otezla. Other income remained elevated, reflecting unrealized gains on equity investments recorded in the period. Year-to-date, net cash provided by operating activities reached $8,355 million, while cash and cash equivalents were $9,445 million at quarter end. Long-term debt declined to $52,434 million from $56,549 million at year-end.
The effective tax rate increased to 18.0% for the quarter. Amgen recorded an additional $400 million noncash impairment to Otezla developed-product-technology rights in Q3 (total $1.2 billion year-to-date) following updates in Medicare price setting under the IRA.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
